Astrid Gendolla
Overview
Explore the profile of Astrid Gendolla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ornello R, Baraldi C, Guerzoni S, Lambru G, Fuccaro M, Raffaelli B, et al.
Front Neurol
. 2022 Jan;
12:774341.
PMID: 34975732
We reported gender-specific data on the efficacy and safety of erenumab, a monoclonal antibody antagonizing the calcitonin gene-related peptide (CGRP) receptor. Our pooled patient-level analysis of real-world data included patients...
12.
Gendolla A, Rauer N, Kraemer S, Schwerdtner I, Straube A
Neurol Ther
. 2021 Nov;
11(1):167-183.
PMID: 34837636
Introduction: Migraine is a neurological disease with a considerable economic and societal burden that negatively impacts quality of life and productivity. Triptans are potent serotonin receptor agonists widely used to...
13.
Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, et al.
Cephalalgia
. 2021 Nov;
42(2):108-118.
PMID: 34743579
Background: We compared the tolerability and efficacy of erenumab, a monoclonal antibody binding to the calcitonin gene-related peptide receptor, to topiramate for migraine prophylaxis in adults. Methods: HER-MES was a...
14.
Overeem L, Peikert A, Hofacker M, Kamm K, Ruscheweyh R, Gendolla A, et al.
Cephalalgia
. 2021 Oct;
42(4-5):291-301.
PMID: 34644203
Background: Switching between antibody classes might be a treatment option in migraine patients who have not responded to one class of a CGRP-(receptor) monoclonal antibody (mAb), but there are no...
15.
Pozo-Rosich P, Gil-Gouveia R, Donnet A, Poole A, Gendolla A, Afridi S, et al.
Eur J Pain
. 2021 Jun;
25(10):2177-2189.
PMID: 34173301
Background: Clinical guidelines agree that preventive treatment should be considered in patients with uncontrolled migraine despite acute medications or patients with ≥4 migraine days per month. However, the criteria to...
16.
Kollewe K, Gaul C, Gendolla A, Sommer K
J Headache Pain
. 2021 Jun;
22(1):50.
PMID: 34078259
Background: Chronic migraine (CM) is associated with substantial economic burden. Real-world data suggests that onabotulinumtoxinA treatment for CM reduces healthcare resource utilisation (HRU) and related costs. Methods: REPOSE was a...
17.
Jedynak J, Eross E, Gendolla A, Rettiganti M, Stauffer V
J Headache Pain
. 2021 May;
22(1):48.
PMID: 34049484
Background: Patients with episodic migraine (EM) with a higher-frequency of migraine headache days (HFEM: 8-14 migraine headache days/month) have a greater disease burden and a higher risk of progressing to...
18.
Eren O, Gaul C, Peikert A, Gendolla A, Ruscheweyh R, Straube A
Sci Rep
. 2020 Jul;
10(1):11382.
PMID: 32647152
Chronic migraine (CM) is a highly disabling primary headache. Botulinum toxin (onabotulinumtoxinA) is effective for treatment of CM, with ~ 50% of patients responding after 24 weeks. A response predictor...
19.
Raffaelli B, Kalantzis R, Mecklenburg J, Overeem L, Neeb L, Gendolla A, et al.
Front Neurol
. 2020 Jun;
11:417.
PMID: 32547474
German authorities reimburse migraine prevention with erenumab only in patients who previously did not have therapeutic success with at least five oral prophylactics or have contraindications to such. In this...
20.
Ashkan K, Sokratous G, Gobel H, Mehta V, Gendolla A, Dowson A, et al.
Acta Neurochir (Wien)
. 2020 May;
162(12):3201-3211.
PMID: 32377948
Background: Migraine is common and ranked as the first cause of disability in people under fifty. Despite significant advances in its pharmacological treatment, it often remains intractable. Neuromodulation is one...